Introduction {#section5-1470320316688345}
============

Angiotensin-converting enzyme (ACE) is a transmembrane zinc metallopeptidase, which has a major role in the metabolism of vasoactive peptides, by converting decapeptide angiotensin I into vasoconstrictor octapeptide angiotensin II and inactivating bradykinin.^[@bibr1-1470320316688345],[@bibr2-1470320316688345]^ ACE is bound to endothelial surface membrane by an anchor peptide, which could be cleft by ACE secretase to form a soluble enzyme called serum ACE.^[@bibr3-1470320316688345]^

In 1990, Rigat et al. found that a polymorphism involving the presence (insertion, I) or absence (deletion, D) of a 287-bp sequence of DNA in intron 16 of the *ACE* gene accounted for approximately half of the variant in serum ACE activity in Caucasians: Individuals with DD genotype had highest serum ACE activity, those with II genotype had the lowest serum ACE activity and those with ID genotype had intermediate serum ACE activity.^[@bibr4-1470320316688345]^ In Asian individuals, *ACE* I/D polymorphism also had a great impact on serum ACE activity, with the same trend as in Caucasians.^[@bibr5-1470320316688345]^

*ACE* polymorphism was correlated to many diseases; for example, atherosclerosis, coronary heart disease, stroke, diabetic nephropathy, and Alzheimer disease.^[@bibr6-1470320316688345][@bibr7-1470320316688345][@bibr8-1470320316688345][@bibr9-1470320316688345]--[@bibr10-1470320316688345]^ It was also reported that *ACE* polymorphism was associated with muscle performance.^[@bibr11-1470320316688345]^ In a previous randomized study, it was reported that ACE inhibitor treatment was effective in increasing bone mineral density (BMD) in a subgroup of women with the *ACE* DD genotype,^[@bibr12-1470320316688345]^ which suggested that *ACE* I/D polymorphism may also correlate with bone metabolism. However, whether there is a relationship between *ACE* I/D polymorphism and BMD still needs further investigation.

It was reported that plasma ACE level determination was more predictive than *ACE* I/D genotype for risk of restenosis after coronary stent, which may due to the large variation of serum ACE activity in different *ACE* I/D genotypes.^[@bibr13-1470320316688345]^ Although serum ACE activity was significantly affected by *ACE* I/D genotype and the serum ACE activity of the DD genotype was nearly twice as high as that of the II genotype, the variation of serum ACE activity in the DD genotype was still very large; as a categorical variable, *ACE* I/D genotype may be less precise than serum ACE activity since it was a continuous variable.^[@bibr4-1470320316688345],[@bibr14-1470320316688345]^ The physiological and pathophysiological effects of serum ACE activity are still not fully understood, and since it was reported that ACE inhibitor treatment can increase the BMD in people with the DD genotype,^[@bibr12-1470320316688345]^ it is interesting to know the relationship between serum ACE activity and bone metabolism.

A previous cross-sectional study showed that ACE inhibitor use was associated with higher BMD in older Chinese, which suggested that angiotensin II may have a detrimental effect on bone; however, in the same cohort study, longitudinal data showed ACE inhibitor use increased bone loss.^[@bibr15-1470320316688345]^ The longitudinal data from another center of the same multicenter cohort study also showed that ACE inhibitor use was associated with increased bone loss.^[@bibr16-1470320316688345]^ So the real relationship between the renin angiotensin system (RAS) and BMD still needs further investigation. In this study, we set out to investigate the relationship between *ACE* I/D polymorphism, serum ACE activity and BMD in older Chinese.

Materials and methods {#section6-1470320316688345}
=====================

Participants were from Mr.OS-Hong Kong and Ms.OS-Hong Kong, which were set up to investigate the risk factors for osteoporotic fracture in Hong Kong-dwelling older Chinese. The inclusive criteria of Mr.OS-Hong Kong and Ms.OS-Hong Kong were almost similar to those of Mr.OS-US, and designed to result in a cohort of older individuals, which is representative of the communities of Hong Kong.^[@bibr17-1470320316688345]^ The study population in Hong Kong consisted of community-dwelling, ambulatory people aged 65 years and above. A total of 4000 individuals (2000 of each gender) were recruited using a combination of private solicitation and public advertising from community centers, housing estates, and the general community in Hong Kong. Stratified sampling was employed to ensure that approximately one-third of the participants fell into each of the following age strata: 65--69, 70--74 and 75 and above years old.^[@bibr18-1470320316688345]^ In this study, people who were taking osteoporosis-related medications, ACE inhibitors and Angiotensin II receptor blockers (ARBs) were excluded from analysis.

A standardized, structured, face-to-face interview was performed to collect demographic information on lifestyle, personal medical history and medication history. Details of information collection methods have been described elsewhere.^[@bibr17-1470320316688345]^ BMD was measured for proximal femur and lumbar spine vertebrate using dual-energy X-ray absorptiometry (DXA) with Hologic QDR 4500 bone densitometers (Hologic, Waltham, MA, USA). Calibration was performed daily on a lumbar spine phantom, and the coefficient of variation was 0.7%.

Peripheral venous blood was taken after overnight fasting for serum isolation and DNA extraction. DNA was later extracted using a standard phenol/chloroform extraction method. I/D genotypes of ACE were determined by polymerase chain reaction (PCR) amplification. PCR mixtures of 25 µl were set up that contained 1X reaction buffer (Fermentas Life Sciences), 2 mM MgCl2, 1 µM of each forward and reverse primer, 0.2 mM each deoxynucleotide (dNTP), 0.6 U Taq polymerase (Fermentas Life Sciences) and 50 ng DNA. The sequences of forward and reverse primer were 5′-AGAGAGACTCAAGCACGCCC-3′ and 5′-ACCCAAGTGCCAGTGATGTT-3′, respectively. The thermal cycling profile began with initial denaturation at 96^o^C for five minutes, followed by 35 cycles of 96^o^C for 30 seconds, 63.8^o^C for 45 seconds, 72^o^C for 30 seconds, and a final extension at 72^o^C for 10 minutes. Amplification products yielded were of 439 bp for the D allele and 727 bp for the I allele. The products were then separated by electrophoresis in 2% agarose gels with ethidium bromide and were visualized under ultraviolet transillumination.

Serum ACE activity was determined photometrically by a commercially available kinetic kit purchased from Bühlmann Laboratories AG (Allschwil, Switzerland). Testing was performed according to the manufacturer's instructions. ACE catalyzes the hydrolysis of the synthetic substance N-\[3-(2-furyl)acryloyl\]-L-phenylalanylglycylglycine, and this hydrolysis results in a decrease in absorbance at 340 nm. The measurement was automatically performed by Roche COBAS MIRA Plus Chemistry Analyzer.

Participants were divided into three groups according to *ACE* I/D polymorphism: II, ID and DD, or four groups according to the serum ACE activity quartile values. Data of continuous variables were presented as mean (SD) and data of categorical variables were presented as numbers (frequency). Continuous variables were compared by analysis of variance (ANOVA) test and categorical variables were compared by Chi-square test. Multiple linear regression analysis was used to examine the relationship between *ACE* I/D polymorphism, serum ACE activity and BMD. Covariates in the regression model was selected according to previous study of the same cohort, which included age, weight, body mass index (BMI), Physical Activity Scale for Elderly (PASE) total score, current smoker, hypertension, diabetes mellitus, coronary heart disease, cardiac failure, chronic obstructive pulmonary disease (COPD), peripheral vascular disease, alpha-blocker, beta-blocker, thiazide diuretics, statin, nitrate, corticosteroid, and calcium supplement use.^[@bibr17-1470320316688345],[@bibr18-1470320316688345]^ A *p* value of less than 0.05 was regarded as statistically significant. All the analyses were performed with SPSS software (version 11.0, Chicago, IL, USA).

Results {#section7-1470320316688345}
=======

After excluding antiosteoporosis drug users, ACE inhibitor users, ARB users and those individuals who did not have *ACE* I/D genotype data because of technical problems with blood samples, 1567 males and 1760 females were selected for analyzing the relationship between *ACE* I/D genotype and BMD. Out of 1567 males, 698 were II genotype, 717 were ID genotype and 152 were DD genotype. Out of 1760 females, 810 were II genotype, 753 were ID genotype, and 197 were DD genotype. The clinical characteristics and drug use of males and females are compared in [Tables 1](#table1-1470320316688345){ref-type="table"} and [2](#table2-1470320316688345){ref-type="table"}, respectively. There were no significant findings in males or females.

###### 

Comparison of clinical features of older men among different *ACE* I/D genotypes.

![](10.1177_1470320316688345-table1)

                                *ACE* genotype   *p* value                       
  ----------------------------- ---------------- --------------- --------------- -------
  Age (years)                   72.6 (5.0)       72.1 (4.9)      72.1 (4.8)      0.794
  Weight (kg)                   62.4 (9.4)       61.7 (8.9)      63.0 (10.5)     0.194
  BMI                           23.42 (3.12)     23.19 (2.95)    23.44 (3.40)    0.329
  PASE total score              97.27 (51.65)    99.20 (52.04)   94.66 (45.03)   0.555
  Current smoker                96 (13.8%)       81 (11.3%)      24 (15.8%)      0.199
  Hypertension                  285 (40.8%)      306 (42.7%)     64 (42.1%)      0.778
  COPD                          74 (10.6%)       87 (12.1%)      14 (9.2%)       0.475
  Coronary heart disease        64 (9.2%)        64 (8.9%)       15 (9.9%)       0.934
  Cardiac failure               24 (3.4%)        24 (3.3%)       1 (0.7%)        0.185
  Diabetes                      84 (12.0%)       81 (11.3%)      18 (11.8%)      0.909
  Peripheral vascular disease   26 (3.7%)        32 (4.5%)       8 (5.3%)        0.624
  Drug use                                                                       
  Alpha blocker                 79 (11.3%)       69 (9.6%)       15 (9.9%)       0.565
  Beta blocker                  106 (15.2%)      95 (13.2%)      22 (14.5%)      0.578
  Thiazide diuretics            20 (2.9%)        26 (3.6%)       5 (3.3%)        0.543
  Statin                        35 (5.0%)        25 (3.5%)       8 (5.3%)        0.311
  Nitrate                       45 (6.4%)        41 (5.7%)       5 (3.3%)        0.318
  Inhaled/oral corticosteroid   7 (1.0%)         10 (1.4%)       2 (1.3%)        0.564
  Calcium supplement            71 (10.2%)       72 (10.0%)      15 (9.9%)       0.992

Data of continuous variables were presented as mean (SD) and data of categorical variables were presented as number (frequency). Continuous variables were compared by ANOVA test and categorical variables were compared by Chi-square test. *ACE*: angiotensin-converting enzyme; I: insertion; D: deletion; BMI: body mass index; PASE: Physical Activity Scale for Elderly; COPD: chronic obstructive pulmonary disease; ANOVA: analysis of variance.

###### 

Comparison of clinical features of older women among different *ACE* I/D genotypes.

![](10.1177_1470320316688345-table2)

                                *ACE* genotype   *p* value                       
  ----------------------------- ---------------- --------------- --------------- -------
  Age (years)                   72.2 (5.3)       72.8 (5.3)      73.3 (6.2)      0.008
  Weight (kg)                   54.4 (8.3)       54.3 (8.5)      54.7 (8.4)      0.803
  BMI                           23.85 (3.33)     23.87 (3.53)    23.90 (3.40)    0.984
  PASE total score              87.83 (34.66)    84.61 (31.70)   84.18 (34.65)   0.116
  Current smoker                11 (1.4%)        19 (2.5%)       4 (2.0%)        0.212
  Hypertension                  327 (40.4%)      325 (43.2%)     88 (44.7%)      0.392
  COPD                          40 (4.9%)        36 (4.8%)       10 (5.1%)       0.981
  Coronary heart disease        67 (8.3%)        69 (9.2%)       13 (6.6%)       0.497
  Cardiac failure               29 (3.6%)        23 (3.1%)       9 (4.6%)        0.569
  Diabetes                      101 (12.5%)      99 (13.1%)      26 (13.2%)      0.911
  Peripheral vascular disease   58 (7.2%)        73 (9.7%)       16 (8.1%)       0.190
  Drug use                                                                       
  Alpha blocker                 3 (0.4%)         6 (0.8%)        5 (2.5%)        0.006
  Beta blocker                  128 (15.8%)      115 (15.3%)     32 (16.2%)      0.929
  Thiazide diuretics            61 (7.5%)        58 (7.7%)       8 (4.1%)        0.191
  Statin                        39 (4.8%)        43 (5.7%)       9 (4.6%)        0.670
  Nitrate                       44 (5.4%)        36 (4.8%)       12 (6.1%)       0.716
  Inhaled/oral corticosteroid   9 (1.1%)         6 (0.8%)        4 (2.0%)        0.579
  Calcium supplement            140 (17.3%)      125 (16.6%)     40 (20.3%)      0.473

Data of continuous variables were presented as mean (SD) and data of categorical variables were presented as number (frequency). Continuous variables were compared by ANOVA test and categorical variables were compared by Chi-square test. ACE: angiotensin-converting enzyme; I: insertion; D: deletion; BMI: body mass index; PASE: Physical Activity Scale for Elderly; COPD: chronic obstructive pulmonary disease; ANOVA: analysis of variance.

There was no significant difference in spine BMD, total hip BMD and femur neck BMD between different *ACE* I/D genotypes in males or females after adjusting for selected confounders. Details are shown in [Table 3](#table3-1470320316688345){ref-type="table"}.

###### 

Comparison of BMD of older individuals among different I/D genotypes.

![](10.1177_1470320316688345-table3)

                   *ACE* genotype   *p* value1    *p* value2            
  ---------------- ---------------- ------------- ------------- ------- -------
  Male             *n* = 698        *n* = 717     *n* = 152             
  Spine BMD        0.94 (0.17)      0.94 (0.18)   0.94 (0.17)   0.931   0.822
  Total hip BMD    0.86 (0.12)      0.86 (0.13)   0.86 (0.13)   0.441   0.410
  Femur neck BMD   0.68 (0.10)      0.68 (0.11)   0.68 (0.11)   0.886   0.858
  Female           n=810            n=753         n=197                 
  Spine BMD        0.75 (0.14)      0.75 (0.15)   0.77 (0.15)   0.182   0.370
  Total hip BMD    0.71 (0.12)      0.70 (0.12)   0.71 (0.12)   0.312   0.745
  Femur neck BMD   0.59 (0.10)      0.58 (0.10)   0.58 (0.10)   0.207   0.478

Multiple linear regression analysis was used to examine the relationship between *ACE* I/D polymorphism and BMD. Covariates in the regression model included age, weight, BMI, PASE total score, current smoker, hypertension, diabetes mellitus, coronary heart disease, cardiac failure, COPD, peripheral vascular disease, alpha-blocker, beta-blocker, thiazide diuretics, statin, nitrate, corticosteroid, and calcium supplement use. (*p* value1: unadjusted *p* value, *p* value2: *p* value adjusted for confounders). BMD: bone mineral density; I: insertion; D: deletion; *ACE*: angiotensin-converting enzyme; PASE: Physical Activity Scale for Elderly.

In total, 1699 males and 1739 females were selected for analyzing the relationship between serum ACE activity and BMD. The quartile values for males and females were 33.6, 44.7, 58.3 and 33.6, 43.3, 56.3, respectively. The clinical characteristics and drug use of males and females are compared in [Tables 4](#table4-1470320316688345){ref-type="table"} and [5](#table5-1470320316688345){ref-type="table"}, respectively. There was no significant difference of clinical characteristics and drug use between different serum ACE activity quartile groups in males or females.

###### 

Comparison of clinical features and drug use of older men between different serum ACE activity quartile groups.

![](10.1177_1470320316688345-table4)

                                Serum ACE activity quartile groups   *p* value                                       
  ----------------------------- ------------------------------------ --------------- --------------- --------------- -------
  Serum ACE activity (U/l)      \<33.6                               33.6--44.7      44.7--58.3      \>58.3          
  Age (years)                   72.1 (4.9)                           72.1 (5.0)      72.5 (5.2)      72.3 (5.1)      0.656
  Weight (kg)                   62.0 (9.1)                           61.8 (9.4)      62.3 (8.7)      61.8 (9.9)      0.838
  BMI                           23.40 (2.97)                         23.24 (3.19)    23.27 (2.87)    23.06 (3.20)    0.432
  PASE total score              97.89 (51.89)                        98.24 (48.74)   97.80 (52.30)   98.88 (52.29)   0.990
  Current smoker                46 (0.8%)                            69 (16.3%)      49 (11.5%)      49 (11.6%)      0.062
  Hypertension                  182 (42.7%)                          184 (43.4%)     177 (41.6%)     174 (41.0%)     0.900
  COPD                          47 (11.0%)                           52 (12.3%)      46 (10.8%)      48 (11.3%)      0.918
  Coronary heart disease        38 (8.9%)                            28 (6.6%)       49 (11.5%)      36 (8.5%)       0.091
  Cardiac failure               17 (4.0%)                            10 (2.4%)       14 (3.3%)       12 (2.8%)       0.564
  Diabetes                      53 (12.4%)                           41 (9.7%)       53 (12.5%)      52 (12.3%)      0.514
  Peripheral vascular disease   16 (3.8%)                            17 (4.0%)       17 (4.0%)       23 (5.4%)       0.618
  Drug use                                                                                                           
  Alpha blocker                 53 (12.4%)                           46 (10.8%)      49 (11.5%)      45 (10.6%)      0.837
  Beta blocker                  61 (14.3%)                           51 (12.0%)      66 (15.5%)      66 (15.6%)      0.416
  Thiazide diuretics            12 (2.8%)                            16 (3.8%)       17 (4.0%)       12 (2.8%)       0.679
  Statin                        25 (5.9%)                            15 (3.5%)       19 (4.5%)       13 (3.1%)       0.187
  Nitrate                       23 (5.4%)                            22 (5.2%)       32 (7.5%)       21 (5.0%)       0.346
  Inhaled/oral corticosteroid   5 (1.2%)                             5 (1.2%)        3 (0.7%)        7 (1.7%)        0.683
  Calcium supplement            40 (9.4%)                            40 (9.4%)       49 (11.5%)      43 (10.1%)      0.706

Data of continuous variables were presented as mean (SD) and data of categorical variables were presented as number (frequency). Continuous variables were compared by ANOVA test and categorical variables were compared by Chi-square test. ACE: angiotensin-converting enzyme; I: insertion; D: deletion; BMI: body mass index; PASE: Physical Activity Scale for Elderly; COPD: chronic obstructive pulmonary disease; ANOVA: analysis of variance.

###### 

Comparison of clinical features and drug use of older women between different serum ACE activity quartile groups.

![](10.1177_1470320316688345-table5)

                                Serum ACE activity quartile groups   *p* value                                       
  ----------------------------- ------------------------------------ --------------- --------------- --------------- -------
  Serum ACE activity (U/l)      \<33.6                               33.6--43.3      43.3--56.3      \>56.3          
  Age (years)                   72.3 (5.2)                           72.8 (5.4)      72.3 (5.0)      72.8 (5.9)      0.241
  Weight (kg)                   54.3 (8.2)                           54.0 (8.2)      54.9 (8.7)      54.2 (8.6)      0.384
  BMI                           23.96 (3.33)                         23.74 (3.27)    24.10 (3.56)    23.67 (3.59)    0.220
  PASE total score              87.44 (31.97)                        87.02 (35.72)   86.47 (32.33)   85.76 (33.08)   0.891
  Current smoker                11 (2.5%)                            6 (1.4%)        10 (2.3%)       5 (1.2%)        0.343
  Hypertension                  183 (42.1%)                          194 (44.3%)     180 (41.6%)     176 (40.6%)     0.732
  COPD                          29 (6.7%)                            14 (3.2%)       20 (4.6%)       24 (5.5%)       0.115
  Coronary heart disease        35 (8.0%)                            39 (8.9%)       42 (9.7%)       35 (8.1%)       0.799
  Cardiac failure               14 (3.2%)                            15 (3.4%)       16 (3.7%)       14 (3.2%)       0.978
  Diabetes                      53 (12.2%)                           47 (10.7%)      61 (14.1%)      58 (13.4%)      0.461
  Peripheral vascular disease   32 (7.4%)                            37 (8.4%)       35 (8.1%)       40 (9.2%)       0.790
  Drug use                                                                                                           
  Alpha blocker                 3 (0.7%)                             3 (0.7%)        3 (0.7%)        6 (1.4%)        0.291
  Beta blocker                  62 (14.3%)                           71 (16.2%)      70 (16.2%)      70 (16.2%)      0.821
  Thiazide diuretics            27 (6.2%)                            27 (6.2%)       38 (8.8%)       34 (7.9%)       0.361
  Statin                        23 (5.3%)                            27 (6.2%)       21 (4.8%)       21 (4.8%)       0.800
  Nitrate                       27 (6.2%)                            21 (4.8%)       24 (5.5%)       23 (5.3%)       0.833
  Inhaled/oral corticosteroid   8 (1.8%)                             3 (0.7%)        2 (0.5%)        7 (1.6%)        0.697
  Calcium supplement            69 (15.9%)                           72 (16.4%)      79 (18.2%)      83 (19.2%)      0.541

Data of continuous variables were presented as mean (SD) and data of categorical variables were presented as number (frequency). Continuous variables were compared by ANOVA test and categorical variables were compared by Chi-square test. ACE: angiotensin-converting enzyme; I: insertion; D: deletion; BMI: body mass index; PASE: Physical Activity Scale for Elderly; COPD: chronic obstructive pulmonary disease; ANOVA: analysis of variance.

After adjusting for selected confounders, there was also no significant difference in spine BMD, total hip BMD and femur neck BMD between different serum ACE activity groups in males and females ([Table 6](#table6-1470320316688345){ref-type="table"}).

###### 

Comparison of BMD of older individuals between different serum ACE activity quartile groups.

![](10.1177_1470320316688345-table6)

                   Serum ACE activity quartile groups   *p* value1    *p* value2                          
  ---------------- ------------------------------------ ------------- ------------- ------------- ------- -------
  Male             *n* = 426                            *n* = 424     *n* = 425     *n* = 424             
  Spine BMD        0.95 (0.19)                          0.93 (0.17)   0.93 (0.17)   0.95 (0.17)   0.327   0.812
  Total hip BMD    0.86 (0.13)                          0.86 (0.13)   0.86 (0.12)   0.86 (0.13)   0.964   0.417
  Femur neck BMD   0.68 (0.11)                          0.69 (0.11)   0.68 (0.11)   0.69 (0.11)   0.676   0.312
  Female           *n* = 435                            *n* = 438     *n* = 433     *n* = 433             
  Spine BMD        0.74 (0.14)                          0.74 (0.15)   0.76 (0.15)   0.76 (0.15)   0.253   0.083
  Total hip BMD    0.70 (0.10)                          0.71 (0.12)   0.71 (0.12)   0.71 (0.12)   0.383   0.444
  Femur neck BMD   0.58 (0.10)                          0.58 (0.10)   0.59 (0.10)   0.58 (0.10)   0.679   0.512

Multiple linear regression analysis was used to examine the relationship between serum ACE activity and BMD. Covariates in the regression model included age, weight, BMI, PASE total score, current smoker, hypertension, diabetes mellitus, coronary heart disease, cardiac failure, COPD, peripheral vascular disease, alpha-blocker, beta-blocker, thiazide diuretics, statin, nitrate, corticosteroid, and calcium supplement use. (*p* value1: unadjusted *p* value, *p* value2: *p* value adjusted for confounders). BMD: bone mineral density; ACE: angiotensin-converting enzyme; PASE: Physical Activity Scale for Elderly; COPD: chronic obstructive pulmonary disease; BMI: body mass index.

Discussion {#section8-1470320316688345}
==========

This cross-sectional study showed that there was no relationship between *ACE* I/D polymorphism and spine, total hip and femur neck BMD in male and female older Chinese individuals.

There were experimental data to suggest that the RAS has an influence on bone health. Angiotensin II directly stimulates DNA and collagen synthesis in osteoblasts^[@bibr19-1470320316688345],[@bibr20-1470320316688345]^ and stimulates osteoclasts when they are co-cultured with osteoblasts.^[@bibr21-1470320316688345]^ It may also influence bone cell metabolism by its effect on blood flow in bone microvasculature, or via its effects on calcium metabolism.^[@bibr22-1470320316688345]^ Lower ACE activity in bone may also lead to a local rise in bradykinin levels, resulting in local vasodilatation.^[@bibr23-1470320316688345]^ This may have a beneficial effect on BMD.^[@bibr24-1470320316688345][@bibr25-1470320316688345]--[@bibr26-1470320316688345]^

Previously, a small cross-sectional study showed that the *ACE* II genotype was associated with higher lumbar spine BMD in postmenopausal women.^[@bibr27-1470320316688345]^ However, another study found that the DD genotype was associated with higher BMD at the lumbar spine in renal failure patients on hemodialysis.^[@bibr28-1470320316688345]^ In a prospective trial of ACE inhibitors in female hypertensive patients for one year, those individuals with the DD genotype had a significant gain in lumbar spine BMD, while women with the other genotypes did not.^[@bibr12-1470320316688345]^ Hip BMD and males were not examined in these studies.

To date, this is the first study to examine the relationship between *ACE* I/D genotypes and BMD in a large unselected group of older Chinese. It was surprising that the results showed no significant difference in BMD between different *ACE* I/D polymorphism groups, as it was previously reported that ACE inhibitor use was associated with higher BMD in older Chinese.^[@bibr18-1470320316688345]^

Based on the average and SD of the total hip BMD of the II genotype group, a group sample size of 150 (as in DD genotype groups in this analysis) should have a power of 80% to detect an average group difference of 0.04 g/cm^2^ at a *p* value of 0.05 level in both sexes, which is similar to the average BMD difference between ACE inhibitor users and non-users at baseline.^[@bibr18-1470320316688345]^ Therefore, the chance of a type one error in detecting a clinically significant difference among the genotype groups was small.

An alternative explanation may be that the *ACE* I/D polymorphism was a categorical variable. Although it has a great impact on serum ACE activity, the variation of serum ACE activity among the same *ACE* genotype group was still very large,^[@bibr4-1470320316688345],[@bibr14-1470320316688345]^ and this variation may confuse the effect of the *ACE* I/D polymorphism on BMD.

In this study, we also examined the relationship between serum ACE activity and BMD. To our surprise, no significant relationship between serum ACE activity and BMD was found in males or females.

A previous study from the same cohort has shown that ACE inhibitor use was associated with higher BMD both in males and females.^[@bibr18-1470320316688345]^ In the same cohort, when grouping the participants by *ACE* I/D polymorphism, it was found that there was no significant difference in BMD between different *ACE* I/D polymorphisms. Although the *ACE* I/D polymorphism had a great impact on serum ACE activity, the inter-individual variation of serum ACE activity in the same *ACE* I/D genotype is still very large,^[@bibr4-1470320316688345],[@bibr14-1470320316688345]^ and this may attenuate the significance of the relationship between *ACE* I/D polymorphism and BMD. So if we subgroup the participants by serum ACE activity, it should provide better significance on BMD than the *ACE* I/D polymorphism.

However, in this study we failed to find a relationship between serum ACE activity and BMD in men and women. As to why there was no significant relationship between serum ACE activity and BMD, the possible reason may be as follows. Although a previous in vitro study showed that angiotensin II was a stimulator of osteoclastic bone resorption,^[@bibr20-1470320316688345]^ a subsequent study demonstrated that angiotensin II indirectly promoted the activation of osteoclasts via upregulation of receptor activator of nuclear factor-kappa B ligand (RANKL) in osteoblasts;^[@bibr29-1470320316688345]^ all these results come from in vitro studies. The relationship between the RAS and BMD may be weak, and intersubject variation of angiotensin II level may not result in significant BMD difference.

To sum up, there was no relationship between *ACE* I/D polymorphism, serum ACE activity and BMD in male or female participants. Combining all these results, it can be speculated that the relationship between RAS and BMD may be weak. In order to clarify the relationship between *ACE* I/D polymorphism, serum ACE activity and bone health, further prospective studies may be needed to provide more conclusive information.

The strengths of this study were the large sample size, non-selective nature of the participants and the adjustment for a wide range of confounders. The limitations may be that the sample was confined to older Chinese and was cross-sectional in nature.
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